Gustaf Wiklund

Associate, Stockholm

Biography

Overview

Gustaf Wiklund is an associate in our Capital Markets practice in Stockholm.

Gustaf has significant experience from advising domestic and international issuers, owners, sponsors and underwriters on a variety of capital markets transactions, including IPOs, rights issues, ABBs and private placements, as well as public M&A transactions, such as international buy-outs. He also advises several listed companies on various corporate governance related matters, including in relation to general meetings and compliance.

Prior to joining White & Case, Gustaf studied Law at Gothenburg School of Business, Economics and Law, and Business Administration, Economics, Project Management and IT at, among other, Uppsala University and Stockholm University.

Education
LLM
Master of Laws
Gothenburg School of Business

Economics and Law, Sweden

Languages
Swedish
English

Experience

Selected representative transactions include:

Optomed EUR 64 million IPO and Nasdaq Helsinki listing
Represented Carnegie Investment Bank as sole global coordinator and joint bookrunner and Swedbank as joint bookrunner in connection with the EUR 64 million IPO and Nasdaq Helsinki listing of Optomed.

Karo Pharma SEK 2.0 billion rights issue
Represented Karo Pharma in connection with its fully underwritten SEK 2.0 billion rights issue.

Oncopeptides SEK 727 million private placement
Represented Jefferies, Carnegie, DNB, Cowen and Kempen as the joint global coordinators and placement agents in connection with the SEK 727 million private placement of shares in Oncopeptides.

Karnov Group SEK 4.2 billion IPO and Nasdaq Stockholm listing
Represented Carnegie and Nordea in connection with the SEK 4.2 billion IPO and Nasdaq Stockholm listing of Karnov Group.

Bridgepoint SEK 9.2 billion public cash offer to shareholders of Cherry
Represented Bridgepoint and European Entertainment Intressenter BidCo AB on the SEK 9.2 billion public cash offer to the shareholders of Cherry.

EQT SEK 6.2 billion public cash offer to shareholders of Karo Pharma
Represented EQT on the SEK 6.2 billion public cash offer to the shareholders of Karo Pharma.

Oncopeptides SEK 546 million private placement
Represented Jefferies, Carnegie and DNB as the joint bookrunners and placement agents in connection with the SEK 546 million private placement of shares in Oncopeptides.

Hoist Finance SEK 568 million private placement
Represented Deutsche Bank and Nordea as the joint bookrunners and placement agents in connection with the SEK 568 million private placement of shares in Hoist Finance.

Arion Banki SEK 3.2 billion IPO and Nasdaq Stockholm and Reykjavik dual-listing
Represented Arion Banki, a leading universal relationship bank in Iceland, and Kaupthing in connection with the SEK 3.2 billion IPO and dual-listing in Stockholm and Reykjavik of Arion Bank.

EQT dual track exit of Piab
Represented EQT in their dual track exit of Piab resulting in the sale to Investor AB (publ) (Patricia Industries) for an enterprise value of SEK 7.0 billion.

Projektengagemang SEK 470 million IPO and Nasdaq Stockholm listing
Represented Projektengagemang and its founders in connection with the 470 million IPO and Nasdaq Stockholm listing of Projektengagemang.

Ovzon SEK 325 million IPO and Nasdaq Stockholm First North Premier listing
Represented Ovzon and its founders in connection with the SEK 325 million IPO and Nasdaq First North Premier listing of Ovzon.

Recipharm SEK 508 million private placement
Represented DNB, Swedbank and Crédit Agricole as placement agents in connection with the SEK 508 million private placement of shares in Recipharm.

Handicare SEK 854.6 million IPO and Nasdaq Stockholm listing
Represented Handicare and its principal shareholder Nordic Capital in connection with the SEK 854.6 million IPO and Nasdaq Stockholm listing of Handicare.

Munters SEK 4.0 billion IPO and Nasdaq Stockholm listing
Represented Carnegie, Goldman Sachs, Danske Bank, Jefferies, Nordea and Swedbank as underwriters in connection with the SEK 4.0 billion IPO and Nasdaq Stockholm listing of Munters.

Boozt SEK 1.6 billion IPO and Nasdaq Stockholm listing
Represented Carnegie, Danske Bank and Berenberg as underwriters in connection with the SEK 1.6 billion IPO and Nasdaq Stockholm listing of Boozt.

Oncopeptides SEK 650 million IPO and Nasdaq Stockholm listing
Represented ABG Sundal Collier, Carnegie and DNB as underwriters in connection with the SEK 650 million IPO and Nasdaq Stockholm listing of Oncopeptides.